The rationale behind targeting GRP78 is that it is overexpressed on the surface of cancer cells, providing them with enhanced survival advantages, including resistance to apoptosis (programmed cell death) and increased tolerance to stress conditions. This evidence concerns the gene HSPA5 and cancer.